Increase in plasma β endorphins precedes vasodepressor syncope

David R Wallbridge, Halina E MacIntyre, Christina E Gray, Martin A Denvir, Keith G Oldroyd, Alan P Rae, Stuart M Cobbe

Abstract

Background—Endogenous opioids have a tonic inhibitory effect on sympathetic tone and have been implicated in the pathophysiology of vasodepressor syncope. Plasma β endorphin concentrations increase after vasodepressor syncope induced by exercise or by fasting.

Aims—To take frequent samples for plasma β endorphin estimation during tilt testing, and to determine whether plasma β endorphin increased before the start of syncope.

Patients—24 patients undergoing tilt testing for investigation of unexplained syncope.

Setting—Tertiary referral centre.

Methods—Blood samples were obtained during 70° head up tilt testing. Plasma β endorphin concentrations were estimated by radioimmunoassay (mean (SD) pmol/l).

Results—Patients with a positive test showed a rise in β endorphin concentrations before syncope (baseline 4·4(1·5) v start of syncope 8·5(3·1), p < 0·002). In contrast, patients with a negative test showed no change in β endorphin concentrations (baseline 3·4(1·0) v end of test 4·5(2·3), NS). After syncope all patients showed a large secondary increase in β endorphins (32·3(18·6)).

Conclusion—An increase in plasma β endorphins precedes vasodepressor syncope. This finding supports a pathophysiological role for endogenous opioids.

(Br Heart J 1994;71:597–599)

Syncope is a common medical problem with multiple potential causes. Vasodepressor (neurocardiogenic) syncope is being increasingly recognised with the introduction of head up tilt testing.1 Although the pathophysiology of this condition is not fully elucidated, hypotension probably results from a sudden reduction in or cessation of sympathetic activity.2 Endogenous opioids seem to exert a tonic inhibitory effect on sympathetic responses to orthostatic stress, and have been implicated in the mechanisms underlying syncope.3 Plasma β endorphins have previously been shown to rise in patients after vasodepressor syncope but it is unclear whether this represents a primary or secondary phenomenon.4 Therefore, we performed frequent blood sampling for plasma β endorphin estimation during tilt tests, to establish whether plasma β endorphins are released before the onset of syncope.

Patients and methods

TILT TEST

We studied 24 consecutive patients (mean (range) age 54·5 (18—77)) undergoing tilt tests for the investigation of unexplained syncope. Table 1 shows the clinical characteristics of the patients. Regular medication was continued before the test. All tests were performed in the fasting state between 0930 and 1230. Patients were tilted 70° head upwards for up to 40 minutes: an angle of at least 60° was required for adequate test sensitivity.5 Non-invasive measurement of blood pressure was performed with Finapress (continuous) and Dinamapp (intermittent) devices. An antecubital venous cannula, inserted 15 minutes before the test, allowed frequent blood sampling. Aliquots of 20 ml were obtained at baseline, and then every 10 minutes, or at the start of symptoms, and after syncope (a maximum of 120 ml per test).

ENDORPHIN ASSAY

β Endorphin was measured by an in house liquid phase radioimmunoassay after extraction from plasma with C18 Sep-Pak cartridges. The primary antiserum cross reacts by 2% with human β lipotrophin (Peninsula Laboratories) and by <0·01% with other related peptides. The sensitivity of the assay is 2 pmol/l. The within batch coefficient of variation over the concentration range 12 to 60 pmol/l was 5%, and 10% at 7 pmol/l. The between batch variation for corresponding ranges was 8% and 12%. Results are given as mean (SD) plasma β endorphin concentrations expressed as pmol/l.

Table 1 Clinical characteristics of patients by tilt test result

<table>
<thead>
<tr>
<th></th>
<th>Positive tilt test</th>
<th>Negative tilt test</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>14</td>
<td>6</td>
</tr>
<tr>
<td>M/F</td>
<td>7/3</td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>54·5 (15—9)</td>
<td>55·5 (14·5)</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>β Blocker or disopyramide</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

Department of Medical Cardiology
D R Wallbridge
M A Denvir
K G Oldroyd
A P Rae
S M Cobbe

Department of Pathological Biochemistry, Royal Infirmary, Glasgow
H E MacIntyre
C E Gray

Correspondence to:
Dr D R Wallbridge,
Department of Medical Cardiology, Royal Infirmary,
10 Alexandra Parade,
Glasgow G31 2ER.

Accepted for publication
22 November 1993
In contrast, the group of patients with a negative test showed little change in plasma β endorphin concentrations during the haemodynamic stress of tilting (baseline 3.4(1.0) vs end of test 4.5(2.3), NS). Only two of 14 patients with a negative test showed a rise in plasma β endorphin concentrations to above the upper limit of normal (fig 2).

When samples were obtained during syncope, four patients showed a small fall in plasma β endorphin concentrations corresponding to the nadir of blood pressure. This fall was not accompanied by parallel changes in human growth hormone, as might be expected from pituitary hypoperfusion. After syncope all patients showed a large secondary increase in plasma β endorphins (32.3(18.6), (fig 3).

REPRODUCIBILITY OF THE ENDOPHIN RESPONSE
Figure 4 shows the plasma β endorphin response during repeat tilt testing in four patients with vasodepressor syncope. The concordant responses include one patient with syncope, one patient with presyncope on repeat tests, and one patient with no rise in plasma β endorphins before vasodepressor syncope on two occasions. Successful treatment with disopyramide in one patient resulted in a negative tilt test with no sustained rise in β endorphin.

HAEMODYNAMIC RESPONSE BEFORE SYNCOPE
Table 2 shows the haemodynamic response to tilt tests. Although there was a wide scatter of results, and a borderline significant rise in heart rate before syncope in the positive test group, no significant differences existed at any time between the heart rates or blood pressures in the positive or negative test groups.
Increase in plasma β endorphins precedes vasodepressor syncope

<table>
<thead>
<tr>
<th>Table 2 Haemodynamic response to tilt tests (mean (SD))</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
</tr>
<tr>
<td>Positive (n = 10):</td>
</tr>
<tr>
<td>Baseline</td>
</tr>
<tr>
<td>Start of syncope</td>
</tr>
<tr>
<td>Negative (n = 14):</td>
</tr>
<tr>
<td>Baseline</td>
</tr>
<tr>
<td>End of test</td>
</tr>
</tbody>
</table>

*p < 0.04 v Baseline (positive); NS v end of test (negative).

Discussion

Tilt testing has facilitated the diagnosis of malignant vasovagal syncope, but understanding of the pathophysiology underlying this condition remains poor. The mechanism of syncope is probably similar to the Bezold-Jarisch reflex. In the face of central hypovolaemia, due either to gravitational effects or to haemorrhage, ventricular diastolic filling may become critically compromised, triggering a cardioprotective reflex involving peripheral vasodilation and bradycardia or asystole. The positive inotropic effect of circulating catecholamines deforms the relatively empty ventricle, triggering mechanoreceptors. Afferent signals in non-myelinated vagal C fibres cause reflex reduction in sympathetic tone and increased vagal activity. How can the normal control of blood pressure by baroreflexes be overridden by vasovagal mechanisms?

Animals studies suggest that endogenous opioid peptides located in the brainstem cardiovascular centres may have an important role. Naloxone, given either intravenously or intracisternally, has been shown to prevent, or reverse, the vasodepressor response in a rabbit model of haemorrhagic shock. In complementary human studies, with incremental lower body negative pressure, naloxone enhances the cardiopulmonary baroreflex excitation of sympathetic activity.

We have shown a rise in plasma β endorphin concentration before the start of symptoms in patients with vasodepressor syncope induced by tilt tests. This contrasts with the remarkably stable plasma β endorphin concentrations found in most patients with a negative test. The reports of a rise in plasma arginine vasopressin before vasovagal syncope raise the possibility that neuroendocrine changes play an important part in sensitising left ventricular baroreceptors to circulating catecholamines. In a canine model it has been shown that the systemic and coronary vasoconstriction that follows an intracerebral dose of the opiate agonist fentanyl is mediated through the release of arginine vasopressin. We have previously shown a correlation between β endorphin and arginine vasopressin concentrations in patients with myocardial ischaemia.

After syncope, all patients show a considerable rise in β endorphins, consistent with a previous report of patients with vasodepressor syncope secondary to either fasting or to exercise. This is clearly part of a wider, non-specific neuroendocrine response to the stress of hypotension, with release of cortisol, arginine vasopressin, aldosterone, angiotensin II, and pancreatic polypeptide. A similar large rise in plasma β endorphin concentration occurs after hypoglycaemia induced by insulin stress (baseline 5.0 v 30 minutes after hypoglycaemia 19.5). In conclusion, a rise in plasma β endorphins precedes vasodepressor syncope.

Endogenous opioid mechanisms seem to be implicated in the pathophysiology of vasodepressor syncope and it is important to examine possible modification of the response with opioid antagonists.

DRW is a British Heart Foundation Friends Provident research fellow.

Increase in plasma beta endorphins precedes vasodepressor syncope.

D. R. Wallbridge, H. E. MacIntyre, C. E. Gray, M. A. Denvir, K. G. Oldroyd, A. P. Rae and S. M. Cobbe

Br Heart J 1994 71: 597-599
doi: 10.1136/hrt.71.6.597

Updated information and services can be found at:
http://heart.bmj.com/content/71/6/597

Email alerting service
These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/71/6/596.2.full.pdf

Notes
Many members will have received the letter from Dr Kenneth Calman, the Chief Medical Officer to the Department of Health, on the implementation of the report Hospital doctors: training for the future.

Dr Calman wrote that Ministers had agreed to the full implementation of the report, which encourages the development of a consultant based service. This will shorten training from an average of 12 years to an average of 7 years with more structured and intensive training. The registrar and senior registrar grades will be unified and the finishing point of specialist training will be decided by the Certificate of Completion of Specialist Training (CCST).

Dr Calman recognised that the present rate of expansion of consultant posts (2%) needs to be increased. Some existing senior registrar appointments will be upgraded to consultant posts. He emphasised two important conditions: firstly, that there will be no overall increase in NHS resources to fund the changes and, secondly, the need to move away from existing medical staffing policies towards more flexible measures that emphasise “local decision making and priorities”.

The NHS Management Executive will be issuing an implementation plan for consultation, but the responsibility for deciding content, direction, and criteria for specialist training rests with individual specialist Royal Colleges and hence though to the SAC in Cardiovascular Medicine and our Training and Manpower Committee. It is important to recognise that the minimum length of training programmes is being reduced but it remains to be seen how much flexibility there will be, especially in terms of funding of the training programmes through the postgraduates. During 1994 the General Medical Council will be consulting on the content of general professional training before specialist training.

The letter recognises many difficulties in achieving the change, including the period immediately after the award of a CCST and the introduction of a national numbering system of trainees. These issues are being taken forward by a working group and an implementation steering group. Furthermore, three expert groups are looking at the training of doctors in academic and research medicine, the training of overseas doctors, and the training of general practitioners. Dr Calman envisages that the change to the new structure will be completed within six years. There are many important changes ahead and the Training and Manpower Committee will be working with the British Cardiac Society Council to ensure that six years from now we have excellent training programmes with appropriate numbers of trainees and adequate numbers of consultants to provide the level of specialist care that patients with cardiac disease have a right to expect. Please send any views you have to the British Cardiac Society.

The following two reports from the Joint Audit Committee and the European Society of Cardiology make it clear that clinical guidelines will play an increasingly important part in everyday practice—we must all be involved.

Joint Audit Committee BCS/RCP London

David de Bono writes in defence of clinical standards: but not of cookbooks:

“The NHS Management Executive has recently (and some would say belatedly) become interested in the concept of writing clinical standards into purchaser-provider contracts. Among documents recently circulated to purchasers as possible source material on which to base such standards was a paper on audit guidelines and clinical standards in stable angina prepared as a summary of a workshop held under the auspices of the Joint Audit Committee of the British Cardiac Society and the Royal College of Physicians. The Joint Audit Committee has since held a further workshop on acute myocardial infarction and intends shortly to hold workshops on heart failure, arrhythmias, and valvar heart disease. It is an attempt to curb the rash diversity of British cardiological practice by imposing rigid guidelines or cookbook protocols! Emphatically not! There is increasing recognition by all parties, not least by purchasers, that the only guidelines likely to be followed—and therefore effective—are those drawn up locally with the involvement of all interested parties including general practitioners with a full understanding of local problems and resources. The two main objectives of the Joint Audit Committee summaries are firstly to provide a brief but accurate description of the clinical condition and a synopsis of recent clinical trial data and second to identify essential features that need to be recorded so that clinical practice can be audited. If clinicians can use this material to help them draw up local guidelines, then our aim will have been fulfilled. In practice, no one can or should expect absolute compliance even with local guidelines: this would be robotic, not medicine. On the other hand, clinicians who depart from locally agreed guidelines should be prepared to justify their action and, even more important, to record their results. When I started in cardiology I was taught to use 8 gauge catheters, always to do a left ventricular angiogram, always to heparinise the patient, and to keep catheter patients in hospital overnight (if not for three or four days). I now do none of these. Changes in management of myocardial infarction, arrhythmias and heart failure have been equally spectacular. But there is no point in being an innovator unless process and outcome are properly recorded so that they can be independently checked, compared with conventional wisdom and, if better, communicated efficiently to others. Purchasers will increasingly seek to write audit funding into individual contracts rather than to deliver it as a lump sum; they can be educated to properly audit innovation as being essential to their own interests as well as those of the provider.”

European Society of Cardiology

Philip Poole-Wilson writes: “Some of you are involved in working groups that prepare guidelines, academic statements or policy statements on areas of interest in cardiology. The Board of the European Society of Cardiology has clarified how these activities should be classified. A task force is established by the board to prepare recommendations or guidelines. Task forces can be proposed to the board by working groups, national societies, or others. The final document needs endorsement by the Board of the European Society of Cardiology and will be published in the European Heart Journal. Study groups can be established by working groups of the European Society of Cardiology to look into specific topics and to prepare opinions and recommendations. These reports reflect the opinions of the study groups and working group. Ideally reports from study groups should be submitted to the European Heart Journal and they almost certainly will be subjected to the normal reviewing process. I do hope that many of you will join task forces or study groups. If there are topics that you think should be evaluated in the context of a working group of the European Society of Cardiology do suggest that to the chairmen of those working groups.

Forthcoming meetings

Jarda Stark is due to give his Tudor Edwards Lecture entitled “Quo vadis paediatric cardiac surgery” on 2 June 1994 at 5.00 pm at the Royal College of Surgeons of England, 35/43 Lincoln’s Inn Fields, London. For further information telephone 071 405 3474.

A second meeting on Cardiovascular Disease Prevention will be held on the 19–22 July 1994 at the Conference Centre, Kensington Town Hall, London. Please contact Hampton Medical Conferences Limited, Hofer House, 185 Uxbridge Road, Hampton, Midd,esex (tel: 081 783 0810) for further information.

D JOHN PARKER
President, British Cardiac Society
JOHN GRIFFITHS
Assistant Secretary, British Cardiac Society,
9 Fitzroy Square, London W1P 5AH

NOTICE

The 1995 Annual Meeting of the British Cardiac Society will take place at the Conference Centre, Harrogate, West Yorkshire from 23 to 25 May.

CORRECTION

Increase in plasma β endorphins precedes vasodepressor syncope D R Wallbridge, H E MacInroy, C E Grov, M A Denes, K G Olbris, A P Rae, S M Cobbe. We regret that owing to a printers’ error all four figures in this article in the May issue (Br Heart J 1994;71:446–8) appeared in the wrong order and with wrong legends. The corrected version of the article is reprinted on pages 597–599 of this issue.